In Vivo Evaluation of the Combined Anticancer Effects of Cisplatin and SAHA in Nonsmall Cell Lung Carcinoma Using [¹⁸F]FAHA and [¹⁸F]FDG PET/CT Imaging

Figure 6

Immunohistochemical staining for AH3 in xenograft tumors. In H441 xenograft tumors, AH3 immunoreactivity was lower in Group A (2 mg/kg cisplatin) and Group B (4 mg/kg cisplatin) than the control group and was almost equal in Group C (4 mg/kg+300 mg/kg SAHA) and the control group. Similar trends were observed in PC14 tumors; however, Group C exhibited a significantly higher increase in AH3 immunoactivity than Group B. Scale bar, 100 μm.